For: | Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World J Clin Cases 2022; 10(22): 7872-7882 [PMID: 36158469 DOI: 10.12998/wjcc.v10.i22.7872] |
---|---|
URL: | https://www.wjgnet.com/2220-3206/full/v10/i22/7872.htm |
Number | Citing Articles |
1 |
Xenia Gonda, Gianluca Serafini, Peter Dome. Fight the Fire: Association of Cytokine Genomic Markers and Suicidal Behavior May Pave the Way for Future Therapies. Journal of Personalized Medicine 2023; 13(7): 1078 doi: 10.3390/jpm13071078
|
2 |
A Halaris, A Sayed, M Hakimi, J Sinacore. Modulation of the inflammatory response exerts beneficial effects on anger in treatment-resistant bipolar depression. Journal of Affective Disorders Reports 2023; 13: 100602 doi: 10.1016/j.jadr.2023.100602
|
3 |
Erhan Kavakbasi, Emma Sampson, Natalie T. Mills, Hikaru Hori, Kathrin Schwarte, Christa Hohoff, K. Oliver Schubert, Scott R. Clark, Célia Fourrier, Bernhard T. Baune. Inflammation‐stratified augmentation of vortioxetine with celecoxib: Results from a double‐blind, randomized, placebo‐controlled trial in major depressive disorder. Journal of Neurochemistry 2023; doi: 10.1111/jnc.15946
|
4 |
Adam Gędek, Zofia Szular, Anna Z. Antosik, Paweł Mierzejewski, Monika Dominiak. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2023; 12(10): 3497 doi: 10.3390/jcm12103497
|
5 |
Rui Sun, Meng-Yu Tang, Dan Yang, Yan-Yi Zhang, Yi-Heng Xu, Yong Qiao, Bin Yu, Shu-Xia Cao, Hao Wang, Hui-Qian Huang, Hong Zhang, Xiao-Ming Li, Hong Lian. C3aR in the medial prefrontal cortex modulates the susceptibility to LPS-induced depressive-like behaviors through glutamatergic neuronal excitability. Progress in Neurobiology 2024; : 102614 doi: 10.1016/j.pneurobio.2024.102614
|
6 |
Ana Salomé Correia, Nuno Vale. Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances. International Journal of Translational Medicine 2024; 4(1): 176 doi: 10.3390/ijtm4010010
|
7 |
Marcel Bertsch-Gout, Anthony T. Reder, Royce Lee. Stress: Immunology and Inflammation. 2024; : 147 doi: 10.1016/B978-0-12-817558-3.00017-2
|
8 |
Monika Dominiak, Adam Gędek, Michalina Sikorska, Paweł Mierzejewski, Marcin Wojnar, Anna Z. Antosik-Wójcińska. Acetylsalicylic Acid and Mood Disorders: A Systematic Review. Pharmaceuticals 2022; 16(1): 67 doi: 10.3390/ph16010067
|
9 |
Sahar Ansari, Hossein Sanjari Moghaddam, Fatemeh A. Basti, Mohammadreza Salehi, Shahin Akhondzadeh. Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research 2023; 174: 111471 doi: 10.1016/j.jpsychores.2023.111471
|
10 |
Bruna R. Kouba, Laura de Araujo Borba, Pedro Borges de Souza, Joana Gil-Mohapel, Ana Lúcia S. Rodrigues. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells 2024; 13(5): 423 doi: 10.3390/cells13050423
|
11 |
Urszula Bąk, Anna Krupa. Challenges and Opportunities for Celecoxib Repurposing. Pharmaceutical Research 2023; 40(10): 2329 doi: 10.1007/s11095-023-03571-4
|